Table 1.

Patient characteristics in each treatment group

Patient characteristics	Total	BSC	IT	CT	ICT	CRT	ICRT
	n = 540	n = 25	n = 31	n = 207	n = 132	n = 118	n = 27
Age (years old)
Median	65	77	71	65	60	69	60
Range (25, 75%)	(58, 73)	(70, 83)	(59, 78)	(59, 73)	(54, 67)	(61, 74)	(51, 67)
Gender
M:F	366:174	17:08	21:10	134:73	79:53	97:21	18:09
(%)	67.8:32.2	68:32	67.8:32.2	64.7:35.2	59.8:40.2	82.2:17.8	66.7:33.3
Stage
III:IV	166:374	8:17	8:23	47:160	21:111	65:53	17:10
(%)	30.7:69.3	32:68	25.8:74.2	22.7:77.3	15.9:84.1	55.1:44.9	63.0:37.0
Histology
Aden:squa	374:126	13:11	20:6	148:43	111:12	63:47	19:7
(%)	74.8:25.2	54.2:45.8	76.9:23.1	77.5:22.5	90.2:9.8	57.3:42.7	73.1:26.9
PS
0:1	322:218	15:10	16:15	131:76	63:69	78:40	19:8
(%)	59.6:40.4	60:40	51.6:48.4	63.3:36.7	47.7:52.3	66.1:33.9	70.4:29.6
Organ metastases
Pleura (%)		0	47.4	6.3	23.3	0	13.6
Lung (%)		23.1	42.1	38.0	31.4	24.6	13.6
Brain (%)		38.5	21.1	27.5	29.1	42.1	45.5
Bone (%)		76.9	10.5	43.0	34.9	24.6	36.4
Liver (%)		23.1	5.3	14.1	9.3	8.8	0
Adrenal glands (%)		0	0	7.7	7.0	14.0	4.5
Others (%)		15.4	21.1	8.5	19.8	12.3	31.8
Mean no. of metastasis sites/patient		1.46	1.47	1.45	1.55	1.26	1.45
Treatment
Platinum + %a	84.8	0	0	86.5	86.3	88.1	88.9
Gefinitib + %b	31.0	0	0	34.7	41.6	18.6	7.4
No. of IT infusions
Median	8.7	–	8.0	–	6.0	–	7.0
Range (25, 75%)	(6.0, 10.0)	–	(6.0, 15.0)	–	(4.5, 10.0)	–	(6.0, 11.0)
Follow-up (mo.)
Median	15.2	4.0	15.2	13.2	17.3	16.3	18.3
Range (25, 75%)	(8.1, 26.9)	(3.0, 6.0)	(7.6, 28.4)	(7.1, 26.4)	(11.2, 27.4)	(9.1, 29.4)	(13.2, 38.6)

BSC best supportive care, IT immunotherapy, CT chemotherapy, ICT immunochemotharapy, CRT chemoradiotherapy, ICRT immuno-chemo-radiation-therapy

^aPlatinum-containing regimens administrated as initial drugs

^bAdministrated as second-line drug